ANB030

ANB030 is an antibody that binds PD-1 in an agonistic manner, leading to reduced T cell activity and anti-inflammatory effects in vivo.   PD-1 is a key inhibitory immune checkpoint receptor expressed by activated T cells.  PD-1 activity contributes to downregulation of T cell mediated immune responses in healthy individuals.

We believe insufficient PD-1 activity may be a key biological defect associated with human inflammatory diseases.  Genetic mutations in the PD-1 pathway are associated with increased susceptibility to various inflammatory conditions (Okazaki and Honjo, Intern Immunol, 2017).  We hypothesize that augmenting PD-1 signaling by ANB030 treatment has the potential to broadly suppress human inflammatory diseases.

ANB030 was developed using AnaptysBio’s proprietary antibody discovery platform.  We believe PD-1 agonist antibodies are challenging to discover due to the unique binding properties required to augment signaling through checkpoint receptors.  ANB030 has been preclinically tested for key pharmacological properties (including binding potency, functional activity, epitope specificity, in vivo efficacy and pharmacokinetics) and manufacturability attributes (including expression and stability).

Through translational biology, we plan to focus the clinical development of ANB030 upon certain human autoimmune diseases where PD-1 checkpoint receptor function may be under-represented.  We presented ex vivo translational data demonstrating the activity of ANB030 in peripheral blood mononuclear cells (PBMCs) from alopecia areata patients at the Festival of Biologics Conference in March 2020 (click here to download).

We are currently conducting a healthy-volunteer Phase 1 clinical of ANB030, which is designed to assess the safety, pharmacokinetics and pharmacodynamic activity of ANB030 in single and multiple ascending cohorts, where top-line data in anticipated during the second half of 2021. We anticipate initiating Phase 2 trials of ANB030 in alopecia areata and vitiligo patients in the fourth quarter of 2021.

To access scientific publications on this topic, please click here.